Hepion Pharmaceuticals, Inc. Skyrocketed

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) rocketted at $19.38, a gain of 117.5%. On Mon, May 22, 2023, HEPA:NASDAQ touched a New 2-Week High of $19.38. The stock got featured on our News Catalysts scanner on Mon, May 22, 2023 at 07:18 AM in the 'BIOTECH' category. From Mon, May 08, 2023, the stock recorded 40.00% Up Days and 45.45% Green Days

About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.